Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 06:30PM GMT
Release Date Price: $85.31 (+2.82%)
Unidentified Participant

Good morning, everyone, and welcome to the J.P. Morgan Healthcare Conference. It is my pleasure to introduce you today to the Blueprint Medicines team. We have Kate Haviland, who is the CEO who will be leading the presentation today. Christy Rossi, who is COO, and Fouad Noumani, who is President, R&D, will be joining Kate during the Q&A. Post the presentation, we will set up some time for Q&A.

With that, I will hand it over to Kate. Kate, thank you so much for joining us here today, and we look forward to the presentation.

Kate Haviland Blueprint Medicines Corp;President and Chief Executive Officer.

Thank you very much, [Malika]. So good morning, everyone, and thank you very much to [Phil Ross] and the entire J.P. Morgan team for inviting us here to present this year. I want to welcome, everyone in the room. It's nice to see so many people here in person and all of those who are joining us online to the webcast.

As [Malika] said, my name is Kate Haviland. I actually joined Blueprint Medicines eight years ago

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot